Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06432621
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-29
First Post:
2024-04-19
Brief Title:
Role of Sugammadex and Neostigmine for Recovery From Rocuronium
Sponsor:
Ain Shams University
Organization:
Ain Shams University
Study Overview
Official Title:
Sugammadex Versus Neostigmine for Recovery of Respiratory Muscle Strength Measured by Ultrasonography in the Postextubation Period in Laparoscopic Cholecystectomy
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
evaluation the reversal of neuromuscular blocking by sugammadex versus neostigmine through assessing the residual neuromuscular blocking effect by ultrasound imaging of expiratory muscle strength and diaphragmatic excursion
Detailed Description:
All patients will be assessed preoperatively by careful history taking history of allergy to rocuronium neostigmine or sugammadex full medical history taking ASA classification and surgical history Premedication with 2mg midazolam Anesthesia will be induced with propofol 1-2 mg kg and fentanyl 1-2 mickg After calibration of TOF train of four rocuronium 06 mgkg will be administered and tracheal intubation will be performed in the absence of train-of four TOF count Rocuronium 015mgkg and Sevoflurane will be used for maintenance of anesthesia
At the end of the surgery patients in group A will receive sugammadex 2 mgkg and patients in group B will receive neostigmine 50 μgkg maximum 5 mg combined with atropine 25 μgkg maximum 25 mg after TOF counts at least exceeding 1 and extubation will be performed in the operating room when the patient is fully awake and fulfilled clinical criteria for extubation
Diaphragm excursion DE reflecting the expiratory and inspiratory muscle strength respectively will be measured via ultrasonography
At the end of the surgery patients in group A will receive sugammadex 2 mgkg and patients in group B will receive neostigmine 50 μgkg maximum 5 mg combined with atropine 25 μgkg maximum 25 mg after TOF counts at least exceeding 1 and extubation will be performed in the operating room when the patient is fully awake and fulfilled clinical criteria for extubation
Diaphragm excursion DE reflecting the expiratory and inspiratory muscle strength respectively will be measured via ultrasonography
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None